eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
.
.
. may 17, 2018
.
.
araka haron
.; author, dr. barbara starfield, revered public health expert at the johns hopkins school of public health; �is us health really the best in the world?�
.